Oxford University presents promising phase II data for malaria vaccine
![](/46/pdcnewsitem/11/86/74/CPHI%20online%20images%20(6).png)
The malaria vaccine R21/Matrix-M, developed by researchers at Oxford University, has produced encouraging new data for the global effort against the mosquito-borne disease.
Oxford University’s malaria vaccine R21/Matrix-M has demonstrated promising new data on its effectiveness against the mosquito-borne disease, potentially carving a way forward from the only WHO-endorsed malaria vaccine currently available, Mosquirix.
Developed and produced by GSK, Mosquirix remains the only malaria vaccine approved by the WHO. It was conceived back in the 1980s, with late-stage trial data published in 2021 establishing an approximately 63% effectiveness rate against clinical malaria. Though GSK has stated plans to produce up to 15 million doses of Mosquirix every year until 2028, this remains well under the approximately 100 million four-dose vaccines required per year to cover 25 million children. GSK has claimed that without funds from international donors, it cannot commit to such a vast demand.
Data from Oxford University, in contrast, has demonstrated a vaccine effectiveness of 80% in a group that received a higher dose of the immune-boosting adjuvant component among over 400 young children who received a fourth dose after the primary three-dose regime. A manufacturing advantage for the Oxford vaccine has also been provided, with a deal with Serum Institute of India to begin producing 200 million doses annually in 2023. Though such data and deals are promising, comparison between Mosquirix and R21/Matrix-M is still tentative as a larger phase III trial for the Oxford vaccine involving 4800 individuals is still underway. “Comparisons between the two vaccines at this stage must be tentative, given they have not yet been compared head-to-head in the same trial,” stated David Conway from the London School of Hygiene & Tropical Medicine.
Alister Craig from the Liverpool School of Tropical Medicine expanded: “However, these phase II data suggest the Oxford shot is a step forward from Mosquirix, improving efficacy and the retention of immunity.”
A key endorsement is expected once Oxford University submits its phase III data to the WHO imminently.
Source: Oxford malaria vaccine data bodes well for effort to combat deadly disease | Reuters
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance